Tag Archives: NCI

May, 2018

24 May
Amgen Enters Groundbreaking Collaboration to Improve Symptom Management During Cancer Treatment

THOUSAND OAKS, Calif., May 23, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Center and the University of California, San Diego (UCSD) Design Lab to support the improvement of cancer outcomes. The L.A.U.N.C.H. (Linking & Amplifying User-Centered Networks …
Share

7 August
NCI Study Identifies Essential Genes for Cancer Immunotherapy

A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don’t respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy. The study, from the National Cancer Institute (NCI), was led by Nicholas …
Share

26 July
Adaptive’s ImmunoSEQ Platform to be Used for Immunosequencing-Based Biomarker Discovery in NCI Trials

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, a pioneer in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors (TCRs and BCRs) of the adaptive immune system, today announced a translational collaboration with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), part of the National Institutes of …
Share
20 July
Kite’s CAR-T Cell Therapy Demonstrates Positive Results in Patients with Chemorefractory Aggressive NHL

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, highlighted the recent online publication of results in Molecular Therapy from a National Cancer Institute (NCI) study of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive NHL including diffuse large B-cell lymphoma (DLBCL). The research, led by James …
Share

26 May
President’s Budget Threatens to Stall Nation’s Progress Against Cancer

ASCO strongly opposes the Administration’s proposed cuts to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including a 21 percent proposed funding cut for the National Institutes of Health (NIH), a 20 percent proposed funding cut for the National Cancer Institute (NCI), and reducing Medicaid funding …
Share

14 November
Pfizer and NCI Collaborate to Study 3 Immunotherapy Agents Targeting Multiple Cancers

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). As part of the CRADA, Pfizer will collaborate with NCI’s Center for Cancer Research (CCR) to arrange …
Share

11 July
International Collaboration to Create New Cancer Models to Accelerate Research

An international project to develop a large, globally accessible, bank of new cancer cell culture models for the research community launches today. The National Cancer Institute (NCI), Cancer Research UK, the Wellcome Trust Sanger Institute and the foundation Hubrecht Organoid Technology are joining forces to develop the Human Cancer Models Initiative (HCMI) …
Share

27 January
MD Anderson Joins US Cancer Centers Endorsing HPV Vaccination for Prevention

In response to low national vaccination rates for the human papillomavirus (HPV), The University of Texas MD Anderson Cancer Center has joined with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a statement calling for increased HPV vaccination for the prevention of cancer. These institutions collectively recognize …
Share